Zealand Pharma A/S American Depositary Shares
ZEAL
ZEAL was delisted on the 29th of September, 2022.
18 hedge funds and large institutions have $78.7M invested in Zealand Pharma A/S American Depositary Shares in 2017 Q3 according to their latest regulatory filings, with 18 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.6M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$18.8M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$12.2M |
| 4 |
AIC
AWM Investment Company
New York
|
+$5.28M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$3.12M |
Top Sellers
ZEAL Hedge Fund Activity: Q3 2017 in Review
18 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Zealand Pharma A/S American Depositary Shares (ZEAL) for Q3 2017, worth a combined $78.7M.
Buyers outnumbered sellers: 18 funds opened new ZEAL positions and 0 closed out — a net gain of 18 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $29.6M.
- 18 institutional investors held Zealand Pharma A/S American Depositary Shares (ZEAL) as of Q3 2017, up from 0 in Q2 2017.
- Funds reported $78.7M of Zealand Pharma A/S American Depositary Shares stock for Q3 2017.
- 18 funds opened new Zealand Pharma A/S American Depositary Shares positions in Q3 2017 and 0 closed out, a net change of +18 holders.
- The largest Zealand Pharma A/S American Depositary Shares buyer in Q3 2017 was Wellington Management Group, an estimated $29.6M added.
Based on aggregated 13F filings for Q3 2017.